Arena Pharmaceuticals (ARNA) 4.31 $ARNA
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.37 (+0.06), AMAG: 34.10 (+0.28), ARNA: 4.31 (+0.09)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.31 (+0.09)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
PR Newswire - Mon Nov 03, 5:30AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.
ARNA: 4.31 (+0.09)
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:34PM CDT
Arena Pharmaceuticals (ARNA) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3.
ACT: 245.32 (-2.18), ARNA: 4.31 (+0.09), HSP: 53.28 (+0.26)
Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting
PR Newswire - Fri Oct 31, 7:37AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. The meeting is taking place November 2-7, 2014, in Boston, Massachusetts. There will be one oral presentation and seven poster presentations.
ARNA: 4.31 (+0.09)
Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
at The Street - Fri Oct 31, 5:40AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RNA: 12.50 (-0.10), HEB: 0.30 (unch), SRPT: 16.38 (-0.02), ARNA: 4.31 (+0.09)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 4.05 (-0.07), ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl
PR Newswire - Tue Oct 28, 5:20PM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the short-term combination of lorcaserin plus phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events compared to therapy with lorcaserin alone.
ARNA: 4.31 (+0.09)
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
PR Newswire - Mon Oct 27, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, November 3, 2014, to provide a corporate update and discuss third quarter 2014 financial results. Arena will release its financial results before the NASDAQ Global Select Market opens that day.
ARNA: 4.31 (+0.09)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 19.19 (-1.76), OREX: 4.05 (-0.07), VVUS: 3.37 (+0.06), ARNA: 4.31 (+0.09)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.97 (-0.06), NPSP: 27.18 (-0.11), MNTA: 10.99 (+0.10), ARNA: 4.31 (+0.09), XOMA: 4.18 (-0.11)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.41 (+0.48), OHRP: 7.07 (-0.09), MNKD: 5.92 (unch), ARNA: 4.31 (+0.09)
Global Anti-Obesity Drugs Market
PR Newswire - Thu Oct 16, 4:07PM CDT
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -
ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
PR Newswire - Fri Oct 10, 10:36AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated with statistically significant weight loss and clinically relevant improvements in cardiometabolic parameters.
ARNA: 4.31 (+0.09)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.05 (-0.07), VVUS: 3.37 (+0.06), NPSP: 27.18 (-0.11), ARNA: 4.31 (+0.09), EXEL: 1.65 (-0.05)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 0.98 (-0.03), AEGR: 21.14 (+0.21), ARNA: 4.31 (+0.09)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 30.28 (+0.09), LLY: 67.17 (+0.63), ABBV: 62.66 (-0.59), SNY: 45.49 (-0.29), MNKD: 5.92 (unch), ENTA: 43.29 (+0.86), ARNA: 4.31 (+0.09), NVS: 91.93 (+0.23)
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.37 (+0.06), AMAG: 34.10 (+0.28), ARNA: 4.31 (+0.09)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.31 (+0.09)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
PR Newswire - Mon Nov 03, 5:30AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.
ARNA: 4.31 (+0.09)
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:34PM CDT
Arena Pharmaceuticals (ARNA) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3.
ACT: 245.32 (-2.18), ARNA: 4.31 (+0.09), HSP: 53.28 (+0.26)
Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting
PR Newswire - Fri Oct 31, 7:37AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. The meeting is taking place November 2-7, 2014, in Boston, Massachusetts. There will be one oral presentation and seven poster presentations.
ARNA: 4.31 (+0.09)
Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
at The Street - Fri Oct 31, 5:40AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RNA: 12.50 (-0.10), HEB: 0.30 (unch), SRPT: 16.38 (-0.02), ARNA: 4.31 (+0.09)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 4.05 (-0.07), ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl
PR Newswire - Tue Oct 28, 5:20PM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the short-term combination of lorcaserin plus phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events compared to therapy with lorcaserin alone.
ARNA: 4.31 (+0.09)
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
PR Newswire - Mon Oct 27, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, November 3, 2014, to provide a corporate update and discuss third quarter 2014 financial results. Arena will release its financial results before the NASDAQ Global Select Market opens that day.
ARNA: 4.31 (+0.09)
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 22, 7:20AM CDT
Source: Flickr user Purple Slog When it comes to the biotech sector there is perhaps no figure more important to investors or the business itself than the cash burn rate. Because most clinical-stage and early commercial stage biotech...
ZFGN: 19.19 (-1.76), OREX: 4.05 (-0.07), VVUS: 3.37 (+0.06), ARNA: 4.31 (+0.09)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.97 (-0.06), NPSP: 27.18 (-0.11), MNTA: 10.99 (+0.10), ARNA: 4.31 (+0.09), XOMA: 4.18 (-0.11)
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.41 (+0.48), OHRP: 7.07 (-0.09), MNKD: 5.92 (unch), ARNA: 4.31 (+0.09)
Global Anti-Obesity Drugs Market
PR Newswire - Thu Oct 16, 4:07PM CDT
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -
ARNA: 4.31 (+0.09)
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
PR Newswire - Fri Oct 10, 10:36AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ® (lorcaserin HCl) was published in the October issue of Postgraduate Medicine, a peer-reviewed medical journal for physicians. In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated with statistically significant weight loss and clinically relevant improvements in cardiometabolic parameters.
ARNA: 4.31 (+0.09)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 4.05 (-0.07), VVUS: 3.37 (+0.06), NPSP: 27.18 (-0.11), ARNA: 4.31 (+0.09), EXEL: 1.65 (-0.05)
The 1 Biotech Stock I'm Definitely Not Buying
Motley Fool Staff - Motley Fool - Tue Oct 07, 7:35AM CDT
Biotechnology stocks are notorious for roller-coaster like highs and lows, but that doesn't mean that every biotech that heads lower will climb again. Figuring out which companies are bargains and which aren't can be particularly tough in this...
DNDN: 0.98 (-0.03), AEGR: 21.14 (+0.21), ARNA: 4.31 (+0.09)
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 06, 9:29AM CDT
Because the average cost of developing and bringing a new drug to market has now surpassed a whopping $5 billion, it has become commonplace for smaller pharmas to license out their first few approved products to larger companies with more resources,...
PFE: 30.28 (+0.09), LLY: 67.17 (+0.63), ABBV: 62.66 (-0.59), SNY: 45.49 (-0.29), MNKD: 5.92 (unch), ENTA: 43.29 (+0.86), ARNA: 4.31 (+0.09), NVS: 91.93 (+0.23)
